NASDAQ •
Healthcare •
Medical Devices •
Quote as of 05/11/2026 15:47
Company Profile
IndustryMedical Devices
SectorHealthcare
ExchangeNASDAQ
Market Capitalization201.11 mln
Float126 mln
Earnings Date05/14/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.36
Borderline
1-Year Forecast
4.10
Transformational upside
Relative Strength
20
/ 100
Significantly lagging
Debt / Equity
2.36
Very high leverage
ROE
-650
Deeply negative
Business Description
Lucid Diagnostics is a New York-based medical diagnostics company focused on reducing deaths from esophageal cancer. Its main offering combines a cell collection device called EsoCheck with a DNA test called EsoGuard, designed to catch early warning signs of esophageal cancer in people who suffer from chronic acid reflux. The company operates as part of the PAVmed group and has been active since 2018.
